Abbott Laboratories (ABT)
Abbott Laboratories (ABT) carries a ŷRobot AI score of 52 out of 100. The model's fair value estimate is $106.06, 2.3% below the last close of $108.59. The chart signal reads Bearish.
| Metric | ABT |
|---|---|
| AI score | 52 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $106.06 |
| Upside to fair value | -2.3% |
| Previous close | $108.59 |
| P/E | 37.41 |
| Price / sales | 3.68 |
| Market cap | $185.75B |
| EPS | 2.74 |
| Revenue growth | 0.9% |
| 1-year price change | 3.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ABT
Is ABT overvalued or undervalued right now?
As of Oct 23, 2026, ŷRobot's fair-value model estimates Abbott Laboratories (ABT) at $106.06 against a last close of $108.59, implying 2.3% downside to the model's estimate.
Is ABT's chart signal bullish or bearish?
The chart-signal model classifies ABT as Neutral as of Nov 13, 2026, with a signal score of -0.09 on a -1 to 1 scale.
What is ABT's ŷRobot AI score?
ABT scores 52 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is ABT stock expensive on P/E and P/S?
ABT trades at 37.4 times earnings and 3.7 times sales as of Nov 13, 2026.
What does ABT's seasonal forecast show?
ŷRobot's seasonal forecast curve for ABT reads +1.6% at 30 days, +4.5% at 90 days, and +3.6% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ABT growing?
Abbott Laboratories's revenue growth is +0.9% and free-cash-flow growth is -0.6% on the latest reported figures.
ABT chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.